The most common adverse events of SA treatment are diarrhea, abdominal pain, cholelithiasis, and cholecystitis, because of the expression of SSTRs at this level, and hyperglycemia caused by the inhibition of SSTR expressed on both insulin producing β-cells and the glucagon-producing α-cells; in the studies included in our meta-analysis no severe adverse effects related to the treatment with SA were reported suggesting a good safety profile (Table 3). The gene discussed is GCG; the disease is Cholecystitis.